Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor…
Vetter Strengthens its Global Clinical Manufacturing Network with Strategic Site Enhancements Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announced significant progress in the continued expansion of its…
Dyve Biosciences and Moffitt Cancer Center Report Promising Study Results for First-of-Its-Kind Topical Therapy Targeting Tumor Acidity Dyve Biosciences, in collaboration with Moffitt Cancer Center, today reported significant study results…
Acumetis Launches as a Single Integrated Brand to Transform Life Sciences Commercialization Acumetis – a new global commercialization company for the life sciences industry – launches today. The company, formed…
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug…
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer Genmab A/S announced today new datademonstrating thatrinatabart sesutecan (Rina-S®), an investigational folate receptor…
Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors Orum Therapeutics, a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of…
Study Finds Biofield Therapy Slows Pancreatic Cancer Progression and Reduces Metastasis Biofield therapy (BT)—a non-invasive, practitioner-administered therapy—can significantly slow the growth and spread of pancreatic cancer in pre-clinical models, according…
Lineage Announces Formation of Scientific Advisory Board Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced…
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted…
AdaptHealth Refinances Credit Facility, Extends Maturity and Lowers Debt Costs AdaptHealth Corp., a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced…
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria Enanta Pharmaceuticals, Inc., a clinical-stage…